5 days ago
Develop Robust In-Licensing Strategies in the Face of GI CGT Market Changes
Explore the evolving landscape of cell and gene therapies (CGTs) in gastroenterology. Key therapies include Anterogen's Cupistem and Takeda's Alofisel, the latter recently withdrawn by EMA. Understand market trends, develop licensing strategies, and identify opportunities in the CGT segment for GI diseases.
Dublin, May 30, 2025 (GLOBE NEWSWIRE) -- The "Cell & Gene Therapies in Dermatology Disorders: Therapeutic Analysis" report has been added to there are only two cell and gene therapies (CGTs) on the market across all gastroenterology (GI) indications.
Anterogen's Cupistem, indicated for the treatment of anal fistula in adult patients, was the first adipose tissue-derived mesenchymal stem cell (ASC) asset to receive approval in the GI market in Japan, 2012. This was followed by Takeda Pharmaceutical's Alofisel (darvadstrocel), which received approval from the European Medicines Agency (EMA) in 2018 and from Japan's Pharmaceuticals and Medical Devices Agency (PDMA) in 2021.
However, on December 13th, 2024, the EMA announced the withdrawal of Alofisel (darvadstrocel) from the EU market citing lack of data that demonstrated the benefit of this therapy in Crohn's marketed therapies are prescribed when a patient has shown an inadequate response to at least one conventional or biologic to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the CGT in Gastrointestinal market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact Gastrointestinal disease targeting CGT therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Company Coverage:
Krystal Biotech Inc
RHEACELL GmbH
Tego Science Inc
Japan Tissue Engineering
Bio Solution International Co Ltd
Organogenesis Holdings Inc
EHL Bio Co Ltd
Castle Creek Biosciences Inc
Abeona Therapeutics Inc
Kangstem Biotech Co Ltd
Key Topics Covered: 1. Preface2. Executive Summary3. Introduction and Scope4. Current Treatment Options4.1. What is Cell & Gene Therapy?4.2. History of the Development of CGT in Dermatology Disorders4.3. Marketed Product Profiles - Cell and Gene Therapy4.4. Challenges and Opportunities in CGT in Dermatology Disorders5. Pricing and Reimbursement Assessment5.1. High Cost of CGTs Requires Adaptation of Payment Models to Ensure Affordability and Patient Access5.2. Price of Cell Therapy6. Regulations6.1. Regulation of CGTs in the 8MM7. Future Market Assessment7.1. Top 20 Dermatology Disorders with CGT Development7.2. Top Five Dermatology Disorders with the Most CGT Pipeline Assets7.3. Top Five Dermatology Disorders Stratified by Molecule Type7.4. CGT in Dermatology Disorders - Pre-reg and Phase II/III7.5. Additional Players Expected to Join the Competition Within Five Years7.6. Industry Trends in the Application of CGTs in Dermatology Disorders7.7. Most of CGT Market Catalyst is Concentrated in 20258. Likelihood of Approval and Phase - Transition Success Rate Analysis8.1. CGT Candidates Have Higher LoA and PTSR vs. Indication Benchmarks9. Sales Forecast9.1. Sales are forecast to reach $1.5 billion by 2030For more information about this report visit
About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
